Social anxiety and fear of bodily sensations in panic disorder and agoraphobia: A matched comparison

1989 ◽  
Vol 11 (2) ◽  
pp. 175-184 ◽  
Author(s):  
Corine de Ruiter ◽  
Bert Garssen
Keyword(s):  
Social Anxiety ◽  
Panic Disorder ◽  
Bodily Sensations ◽  
Fear Of Bodily Sensations ◽  
Matched Comparison ◽  
Anxiety And Fear

Early Maladaptive Schemas in Patients With Panic Disorder With Agoraphobia

2001 ◽  
Vol 15 (2) ◽  
pp. 131-142 ◽  
Author(s):  
Liv M. Hedley ◽  
Asle Hoffart ◽  
Harold Sexton
Keyword(s):  
Panic Disorder ◽  
Schema Theory ◽  
Early Maladaptive Schemas ◽  
Loss Of Control ◽  
Maladaptive Schemas ◽  
Treatment Start ◽  
Modeling Techniques ◽  
Bodily Sensations ◽  
Fear Of Bodily Sensations

The present study explored the relationships among Early Maladaptive Schemas (EMS), beliefs about loss of control, a fear of bodily sensations, and avoidance in patients undergoing cognitive therapy. Fifty-nine patients (43 women and 16 men) being treated for panic disorder with agoraphobia (PDA) participated in the study. Two EMS that are seen as being central in PDA [vulnerability to harm (VH) and functional incompetence/dependency (DI)], beliefs about loss of control, a fear of bodily sensations, and avoidance were measured at treatment start and at six months follow-up. The data were analyzed using structural modeling techniques. The VH schema influenced beliefs about loss of control, a fear of bodily sensations, and avoidance. Beliefs about loss of control, in turn, predicted a fear of bodily sensations. DI was predicted by VH and did not influence other aspects of PDA. The results were largely in consort with the theoretical suppositions of schema theory and indicated that the VH schema may contribute to the maintenance of PDA.

Epinephrine and fear of bodily sensations in panic disorder and social phobia

1996 ◽  
Vol 10 (4) ◽  
pp. 259-265 ◽  
Author(s):  
Dirk J. Veltman ◽  
Gudo van Zijderveld ◽  
Fred J H. Tilders ◽  
Richard van Dyck
Keyword(s):  
Panic Disorder ◽  
Social Phobia ◽  
Bodily Sensations ◽  
Fear Of Bodily Sensations

scholarly journals Changes in respiration mediate changes in fear of bodily sensations in panic disorder

2009 ◽  
Vol 43 (6) ◽  
pp. 634-641 ◽  
Author(s):  
Alicia E. Meuret ◽  
David Rosenfield ◽  
Stefan G. Hofmann ◽  
Michael K. Suvak ◽  
Walton T. Roth
Keyword(s):  
Panic Disorder ◽  
Bodily Sensations ◽  
Fear Of Bodily Sensations

Alexithymia, Fear of Bodily Sensations, and Somatosensory Amplification in Young Outpatients With Panic Disorder

2007 ◽  
Vol 48 (3) ◽  
pp. 239-246 ◽  
Author(s):  
Domenico De Berardis ◽  
Daniela Campanella ◽  
Francesco Gambi ◽  
Raffaella La Rovere ◽  
Gianna Sepede ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Somatosensory Amplification ◽  
Bodily Sensations ◽  
Fear Of Bodily Sensations

A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder

2010 ◽  
Vol 41 (2) ◽  
pp. 373-383 ◽  
Author(s):  
D. Koszycki ◽  
M. Taljaard ◽  
Z. Segal ◽  
J. Bradwejn
Keyword(s):  
Panic Disorder ◽  
Behavior Therapy ◽  
Cognitive Behavior Therapy ◽  
Panic Attacks ◽  
Cognitive Behavior ◽  
Secondary Analyses ◽  
Bodily Sensations ◽  
Rate Of Decline ◽  
Fear Of Bodily Sensations ◽  
Over Time

BackgroundSelf-administered cognitive behavior therapy (SCBT) has been shown to be an effective alternative to therapist-delivered treatment for panic disorder (PD). However, it is unknown whether combining SCBT and antidepressants can improve treatment. This trial evaluated the efficacy of SCBT and sertraline, alone or in combination, in PD.MethodPatients (n=251) were randomized to 12 weeks of either placebo drug, placebo drug plus SCBT, sertraline, or sertraline plus SCBT. Those who improved after 12 weeks of acute treatment received treatment for an additional 12 weeks. Outcome measures included core PD symptoms (panic attacks, anticipatory anxiety, agoraphobic avoidance), dysfunctional cognitions (fear of bodily sensations, agoraphobic cognitions), disability, and clinical global impression of severity and improvement. Efficacy data were analyzed using general and generalized linear mixed models.ResultsPrimary analyses of trends over time revealed that sertraline/SCBT produced a significantly greater rate of decline in fear of bodily sensations compared to sertraline, placebo/SCBT and placebo. Trends in other outcomes were not significantly different over time. Secondary analyses of mean scores at week 12 revealed that sertraline/SCBT fared better on several outcomes than placebo, with improvement being maintained at the end of continuation treatment. Outcome did not differ between placebo and either sertraline monotherapy or placebo/SCBT. Moreover, few differences emerged between the active interventions.ConclusionsThis trial suggests that sertraline combined with SCBT may be an effective treatment for PD. The study could not confirm the efficacy of sertraline monotherapy or SCBT without concomitant medication or therapist assistance in the treatment of PD.

Comparison of Social Anxiety in Patients with Social Phobia and Panic Disorder

1987 ◽  
Vol 175 (1) ◽  
pp. 49-51 ◽  
Author(s):  
DENNIS J. MUNJACK ◽  
RICHARD A. BROWN ◽  
DIANE E. MCDOWELL
Keyword(s):  
Social Anxiety ◽  
Panic Disorder ◽  
Social Phobia

scholarly journals Long-Term Effectiveness and Cost-Effectiveness of Videoconference-Delivered Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder, Panic Disorder, and Social Anxiety Disorder in Japan: One-Year Follow-Up of a Single-Arm Trial (Preprint)

2019 ◽  
Author(s):  
Kazuki Matsumoto ◽  
Sayo Hamatani ◽  
Kazue Nagai ◽  
Chihiro Sutoh ◽  
Akiko Nakagawa ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Anxiety Disorder ◽  
Social Anxiety ◽  
Panic Disorder ◽  
Social Anxiety Disorder ◽  
Behavioral Therapy ◽  
Obsessive Compulsive ◽  
Compulsive Disorder

BACKGROUND Face-to-face individual cognitive behavioral therapy (CBT) and internet-based CBT (ICBT) without videoconferencing are known to have long-term effectiveness for obsessive-compulsive disorder (OCD), panic disorder (PD), and social anxiety disorder (SAD). However, videoconference-delivered CBT (VCBT) has not been investigated regarding its long-term effectiveness and cost-effectiveness. OBJECTIVE The purpose of this study was to investigate the long-term effectiveness and cost-effectiveness of VCBT for patients with OCD, PD, or SAD in Japan via a 1-year follow-up to our previous 16-week single-arm study. METHODS Written informed consent was obtained from 25 of 29 eligible patients with OCD, PD, and SAD who had completed VCBT in our clinical trial. Participants were assessed at baseline, end of treatment, and at the follow-up end points of 3, 6, and 12 months. Outcomes were the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), Panic Disorder Severity Scale (PDSS), Liebowitz Social Anxiety Scale (LSAS), Patient Health Questionnaire–9 (PHQ-9), General Anxiety Disorder–7 (GAD-7), and EuroQol-5D-5L (EQ-5D-5L). To analyze long-term effectiveness, we used mixed-model analysis of variance. To analyze cost-effectiveness, we employed relevant public data and derived data on VCBT implementation costs from Japanese national health insurance data. RESULTS Four males and 21 females with an average age of 35.1 (SD 8.6) years participated in the 1-year follow-up study. Principal diagnoses were OCD (n=10), PD (n=7), and SAD (n=8). The change at 12 months on the Y-BOCS was −4.1 (<i>F</i><sub>1</sub>=4.45, <i>P</i>=.04), the change in PDSS was −4.4 (<i>F</i><sub>1</sub>=6.83, <i>P</i>=.001), and the change in LSAS was −30.9 (<i>F</i><sub>1</sub>=6.73, <i>P</i>=.01). The change in the PHQ-9 at 12 months was −2.7 (<i>F</i><sub>1</sub>=7.72, <i>P</i>=.007), and the change in the GAD-7 was −3.0 (<i>F</i><sub>1</sub>=7.09, <i>P</i>=.009). QALY at 12 months was 0.7469 (SE 0.0353, 95% Cl 0.6728-0.821), and the change was a significant increase of 0.0379 (<i>P</i>=.01). Total costs to provide the VCBT were ¥60,800 to ¥81,960 per patient. The set threshold was ¥189,500 ($1723, €1579, and £1354) calculated based on willingness to pay in Japan. CONCLUSIONS VCBT was a cost-effective way to effectively treat Japanese patients with OCD, PD, or SAD. CLINICALTRIAL University Hospital Medical Information Network Clinical Trials Registry UMIN000026609; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030495

Sign in / Sign up

Export Citation Format

Share Document